Cambridge NeuroScience Cerestat
Executive Summary
Preliminary analyses of discontinued Phase III trials in stroke and traumatic brain injury demonstrates potential therapeutic benefit in a subset of the stroke population. CNSI and partner Boehringer Ingleheim will further evaluate data on the 620 patients from the stroke trial and expect to decide by the second quarter of 1998 if further clinical trials are warranted. CNSI will lay off 30 of its 60 staffers, taking an $800,000 charge against earnings. Eleven scientists will remain in ion-channel research, including the ophthalmology work with Allergan, and five scientists will work on growth factor research. The company is considering the sale of some or all of its technology assets...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth